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Monoclonal antibodies (mAbs) are a dominant class of protein-based drugs used in multiple therapeutic 
contexts. These drugs have revolutionised the management of a number conditions and are positioned 
as an important strategy in tailored pharmaceutical approaches (targeted therapy) for 
immunomodulation and oncological management. The in vivo formulation of proteins, including 
antibodies, is a complex process tightly regulated through environmental factors and homeostatic 
mechanisms. Reproduction of these conditions is essential during ex vivo manufacture of mAbs to 
ensure the stability of proteins and to prevent aggregation, which may impact on the efficacy of the 
agent in biological tissue. Among these environmental factors, temperature pH, buffer characteristics, 
and the use of excipients, including salts, sugars, surfactants and amino acids are of paramount 
importance. The focus of the present paper was to provide an overview of contemporary literature, with 
a focus on key studies performed by the author and colleagues, focusing on how excipient use and 
instrumental monitoring of stability and aggregation in mAbs could have the potential to influence future 
drug design and protein formulation practice.  
 
Analysis of the data set suggested that the regulation of these features during the formulation of mAbs 
is a complex process and there is a need to ensure that all processes within the manufacture of mAbs are 
controlled according to the relevant environmental factors influencing protein stability and aggregation. 
This paper highlights the use of adherent and non-adherent cell lines to investigate the ability of 
excipients to maintain mAb stability. The specific excipients analysed including amino acids (arginine 
and glutamate), and combinations/comparison of ionic excipients in solution, pH and dynamics of 
solutions, including protein-protein interactions, concentrations and agglomeration. It was demonstrated 
in these studies that excipients have specific and contrasting effects on mAb stability and aggregation 
potential. Furthermore, characterisation of the effects of excipients and formulation techniques provided 
a key insight into the role of these factors in maintaining mAb stability, while instrumental techniques 
were evaluated during the characterisation of stability and agglomeration in a variety of contexts.  
 
The majority of this paper reflects the culmination of six published papers, in which the author has 
actively participated, focusing on the application of instrumental analysis methods to the 
characterisation of mAb formulations. These studies highlight a broad range of techniques used to 
characterise protein formulations and which may be applied to mAbs, including nuclear magnetic 
resonance (NMR) spectroscopy and orthogonal techniques. Characterisation of the size of protein/mAb 
aggregates has been demonstrated, with pharmaceutical relevance, including in the design of pro-drugs. 





using multiple models, providing a comprehensive insight into this topic. The included studies indicate 
that additives that disrupt protein-protein interactions and prevent aggregation can influence mAb 
stability and that the stabilisation characteristics of these proteins can be measured using instrumental 
techniques. These studies have clear implications for the use of instrumental analysis in the development 
of therapeutic mAbs, highlighting the need for further research in this field, including further 







I would like to express my sincere gratitude to Professor Mark Smales for his amazing support, guidance 
and patience during the writing of this thesis. He has pushed me to be able to achieve a qualification 
that I thought was past me. 
I would like to express a huge thank you to all the academic PI’s and co-authors of the papers that form 
the basis of this thesis.  They have all been amazing and it’s been a wonderful scientific journey with 
them in the quest of enhancing formulation knowledge. 
Thank you for all supporting my application for this degree. 







Declaration ............................................................................................................................................. 3 
Abstract ................................................................................................................................................... 4 
Acknowledgements ................................................................................................................................ 6 
1.0 Background to the Thesis .............................................................................................................. 10 
1.1 General Introduction to Monoclonal Antibodies .................................................................... 12 
1.2 Aims and objectives of the work described in this thesis ....................................................... 20 
1.3 Literature review, including published work by the candidate ............................................. 20 
1.3.1 General Approach to Formulation of Biotherapeutic Proteins, Particularly mAbs ............... 22 
1.3.2 Excipients in mAb formulation ............................................................................................. 23 
1.3.3 Paper 1: Kheddo P, Cliff MJ, Uddin S, van der Walle CF, Golovanov AP (2016) 
Characterizing monoclonal antibody formulations in arginine glutamate solutions using 1H NMR 
spectroscopy, MAbs 8(7):1245-1245. ............................................................................................ 26 
1.3.4 Paper 2: Kheddo, P., Golovanov, A. P., Mellody, K. T., Uddin, S., van der Walle, C. F., & 
Dearman, R. J. (2016). The effects of arginine glutamate, a promising excipient for protein 
formulation, on cell viability: Comparisons with NaCl. Toxicology in Vitro, 33: 88-98. .............. 43 
1.3.5 Paper 3: Hamrang, Z., Hussain, M., Tingey, K., Tracka, M., Casas‐Finet, J. R., Uddin, S., et 
al. (2015). Characterisation of stress‐Induced aggregate size distributions and morphological 
changes of a Bi‐Specific antibody using orthogonal techniques. Journal of Pharmaceutical 
Sciences, 104(8): 2473-2481. ......................................................................................................... 55 
1.3.6 Paper 4: Gonçalves, A. D., Alexander, C., Roberts, C. J., Spain, S. G., Uddin, S., & Allen, 
S. (2016). The effect of protein concentration on the viscosity of a recombinant albumin solution 
formulation. RSC Advances, 6(18): 15143-15154. ......................................................................... 67 
1.3.7 Paper 5: Ouberai, M.M., Dos Santos, A.L.G., Kinna, S., Madalli, S., Hornigold, D.C., 





bioactivity of a peptide hormone in vivo by reversible self-assembly. Nature 
Communications, 8(1), p.1026. ...................................................................................................... 84 
1.3.8 Paper 6: Zapadka, K. L., Becher, F. J., Uddin, S., Varley, P. G., Bishop, S., Gomes dos 
Santos, A. L., & Jackson, S. E. (2016). A pH-induced switch in human glucagon-like peptide-1 
aggregation kinetics. Journal of the American Chemical Society, 138(50): 16259-16265. ........... 94 
3.1 Application of NMR spectroscopy in characterisation of monoclonal antibodies ............. 103 
3.2 Application of orthogonal techniques in Characterisation of stress-induced antibody 
aggregates ........................................................................................................................................ 105 
3.3 Investigation of dynamical allostery effects in mutated scFV antibody fragments and 
stabilising/destabilising effects ...................................................................................................... 108 
3.4. Oxm self-assembles into fibrillar nanostructures ................................................................ 108 
3.5. Protein concentration effects on albumin solution viscosity ............................................... 109 
3.5 Aggregation kinetics of a pH-induced switch of human glucagon-like peptide 1 .............. 111 
4.0 General Discussion ....................................................................................................................... 114 
5.0 Conclusions ................................................................................................................................... 118 






Table of Figures 
Figure 1.1: Antibody structure. Schematic representation of an antibody (left) and immunoglobulin G (right), 
adapted from (Merck KGaA, 2015, p. 9)...................................................................................................... 12 
Figure 1.2: Antibody Fab region. Fragment antigen binding (Fab region) in antibodies, adapted from (Merck 
KGaA, 2015, p. 10) ...................................................................................................................................... 15 
Figure 1.3: Additional antibody structures.  scFv (single-chain variable domain), VL (variable light chain 
regions), VH (Variable heavy chain regions) in antibodies, adapted from (Merck KGaA, 2015, p. 17) ..... 15 
Figure 1.4: Modern analytical methods employed in particle characterisation and the range of sizes over which 
these can be used to measure particles, adapted from (Hamrang, et al., 2015, p. 2474). MALLS refers to 
multi-angle laser light scattering technique, FFF refers to field-flow fractionation, AUC is analytical 
ultracentrifugation, CE-SDS is capillary electrophoresis-sodium dodecyl sulphate and SEC is size 
exclusion chromatography (Hamrang, et al., 2015, p. 2474)........................................................................ 56 
Figure 3.1: Correlation between the addition of arginine glutamate and NMR signals of monoclonal antibodies, 
adapted from (Kheddo, et al., 2016, p. 1246). ............................................................................................ 103 
Figure 3.2: Representation of NMR long-term data, describing changes in monoclonal antibodies in the 
analysed formulations, adapted from (Kheddo, et al., 2016, p. 1248). ....................................................... 104 
Figure 3.3: Representation of NMR long-term data, describing changes in monoclonal antibodies in the 
analysed formulations, adapted from (Kheddo, et al., 2016, p. 1248). ....................................................... 105 
Figure 3.4: The correlations between percentages of surviving cells and osmolality of the tested solutions 
(Kheddo, et al., 2016, p. 91) Trends were presented as correlations between percentage of viable cells 
versus cumulative osmolality (A, C) or solution concentration (B, D). The correlation between the tested 
salt concentrations and cumulative osmolality was represented on the figure E. In figure 3.4 above, the 
corresponding correlation between concentration of the introduced salts and the observed osmolality levels 
are outlined in plot E. In turn, culture viability was established with the aid of a flow cytometer and is 
presented in the format of the proportion of cells that survive. Correlations between the percentage of 
surviving cells and osmolality are outlined in figure 3.4A, while the effect of solution concentration on 
culture viability is represented in figure 3.4B. ........................................................................................... 107 
Figure 3.6: Rheology data of human recombinant albumin solutions, adapted from (Goncalves, et al., 2013, p. 
10) ............................................................................................................................................................... 110 
Figure 3.7: Correlation plots between protein concentration, viscosity and peak area, adapted from (Goncalves, 
et al., 2013, p. 10). ...................................................................................................................................... 111 
Figure 3.8: GLP-1 aggregation kinetics represented as a function between various pH levels and protein 
concentrations, adapted from (Zapadka, et al., 2016, p. 3) ......................................................................... 112 
Figure 3.9: Representation of size distributions of protein samples at various pH levels, adapted from (Zapadka, 







1.0 Background to the Thesis 
This thesis is submitted for consideration based upon a track record of work and publication over a 
period of time around the broad area of stabilising biotherapeutic protein formulations destined for use 
in the clinic to treat a range of diseases. The papers put forward for consideration under this, and the 
contributions I made to each of these studies, are as follows (full versions of the papers are included in 
Appendix A); 
 
1. “Characterizing monoclonal antibody formulations in arginine glutamate solutions using 1H NMR 
spectroscopy” by Kheddo and co-workers (Kheddo, et al., 2016) 
Candidates Contribution: I initiated the project and was one of the main industrial supervisors for this 
project.  NMR is a unique innovative technique that has not been fully utilised for full antibodies. Work 
was directed from a formulation standpoint by myself to understand the impact of the technique as well 
as impact of the Arg-Glu formulation.  Study design, student supervision, data decision, and research 
direction as well as manuscript review was carried out by me. 
 
2. “The effects of arginine glutamate, a promising excipient for protein formulation, on cell viability: 
Comparisons with NaCl” by Kheddo and co-workers (Kheddo, et al., 2016) 
Candidates Contribution: My group is always on the lookout for novel excipients.  This research 
explored arg-glu as a novel stabilising excipient.  I drove the research application from a formulation 
perspective, directing, supervising, teaching the student.  The awareness and direction also related to 
the academic PI, the science behind formulation and stability. Student was additionally supervised by 
myself in my lab at MedImmune. 
 
3. “Characterisation of Stress-Induced Aggregate Size Distributions and Morphological Changes of a 
Bi-Specific Antibody Using Orthogonal Techniques” by Hamrang and co-workers (Hamrang, et al., 
2015, p. 2473) 
Candidates Contribution: Supervised the student from an industrial perspective.  Making the student 
and academic PI aware of the impact of their research and relevance.  The direction included, study 
design, data interrogation, manuscript review as well future study requirements. 
 
4. “Controllin the bioactivity of a peptide hormone in vivo by reversible self-assembly” by Myriam M. 
Ouberai and co-workers (Ouberai et al., 2017) 
Candidates’ contribution: student was guided on different ways through which bioactivity of peptide 





a new drug with high levels of efficacy and safety was explained. Through in-depth experiments, the 
student was in a good position to understand every aspect and was guided in the laboratory which 
enhanced clear understanding of different concepts.  
 
5. “The effect of protein concentration on the viscosity of a recombinant albumin solution formulation” 
by Goncalves and co-workers (Goncalves, et al., 2013, p. 1) 
Candidates Contribution: Primary industrial supervisor for this project.  Again directed the research in 
relation to its applicability to the formulation sector.  Direction of project ranged from study design, 
data interpretation and interrogation, presentation and manuscript review and approval.  Student was 
also supervised in my lab, which required hands-on support as well as direction. 
 
6. “A pH-Induced Switch in Human Glucagon-like Peptide-1 Aggregation Kinetics” by Zapadka and 
co-workers (Zapadka, et al., 2016). 
Candidates Contribution: 
Evidence to confirm my contribution is provided in Appendix B, which includes an email from the 
corresponding author of each paper outlining their interpretation of my contribution. These were 
obtained independent from myself and by my academic supervisor for this thesis. The remainder of this 
thesis provides a general introduction to the area of formulation sciences and developments within this 
and then explains the findings of each of the papers above. A general discussion is then provided that 
attempts to place the findings of these studies in the wider context of the primary literature. The papers 






1.1 General Introduction to Monoclonal Antibodies 
Monoclonal antibodies (mAb) are of paramount importance in modern biomedical research and 
for the treatment of an ever-widening number of diseases (Clark & Pazdernik, 2015, p. 74). These 
reagents are employed during diagnosis of diseases as well as in treatment of cancer, autoimmune 
diseases, rheumatoid arthritis and other diseases and infections. Monoclonal antibodies can be 
characterised as antibodies generated from a single cell line or a single clone, forming identical antibody 
molecules. A schematic diagram of an antibody is presented in Figure 1.1 below. 
 
Figure 1.1: Antibody structure. Schematic representation of an antibody (left) and immunoglobulin G 
(right), adapted from (Merck KGaA, 2015, p. 9) 
 
The use of mAbs in biomedical research has proven to be important in providing reagents for 
the identification of nucleic acids, proteins, carbohydrates as well as other biologically active molecules 
in numerous basic science studies. Application of mAbs in biomedical investigations has resulted in the 
identification of molecules that control replication of cells, differentiation processes and advanced 
general knowledge in the corresponding relationship between structures of biologically active molecules 
and their functions (Weiner et al., 2010, p.317). Such advances in biological sciences have improved 
our understanding of host responses to toxins and disease agents, to tumours (spontaneously transformed 
cells), to transplanted tissues and organs and to autoimmunity forming molecules.  
Formulation development is vital in proteins as it ensures excellent stability, supporting chemical 
and physiochemical process. Also, biologics are susceptible to structural instabilities due to their 
complex structure and also being very sensitive to environmental factors. Each protein is distinct in its 
way. Therefore, this makes it hard for them to guess or have an optimum formulation condition. Any 
structural perpetration can also disrupt proteins causing it to lose its biological activity or even 





transportation and its delivery to patients. There are several conditions one has to consider when 
developing optimum formulation conditions. These conditions or factors might include: 
• Protein concentration 
• Delivery options 
• Container or closure systems 
• Stresses 
• Lyophilization involves freeze-drying or freezing the product, lowering its pressure and 
later removing the ice through sublimation  
• Stability indicating assays 
• Degradation pathways 
Proteins formulation is a critical step which is overly overshadowed and can easily hinder drugs 
development. Many developers do not take into consideration the amount of time needed to formulate 
and can result in a diminished product and choosing too long might as well hinder the ability of the drug 
to make it to the market before completion. Failure to understand the protein properties thoroughly and 
nature will delay the formulation and result in poor results from the start, resulting in a commodity not 
fit for commercialization. As a way of formulating a drug, some responsibilities need to be adhered to 
develop a viable drug that is clinically and commercially viable. Drugs require at least two years of shelf 
life, some requiring as long as three years, 100-150 mg/ml for RIA with lower concentrations being 
okay for oncology, requires high potent immunotherapy, and mostly required as a liquid for RIA with 
lyophilized drugs mostly recommended for oncology. For a product or a prescription to be commercially 
viable, there must be a formulated and appropriate way or mode of delivery and their presentations 
should be specified by TPPs like vials and other devices. The drug should then have a manufacturing 
process and plans for clinical trials. 
Biopharmaceutical technology is a new model of drug development that has led to the shifting 
of drug development from small molecule to abundant molecules proteins. The drugs have caused a 
shift in diseases to cure enhancing the quality of health and life in general, more so to patients with 
diseases like refractory cancer, and other autoimmune diseases. Since USFDA approved the first 
biopharmaceutical product in 1982, the number of products has increased rapidly with monoclonal 
antibodies like zenapax and proleukin being introduced in successive years. However, production is 
very stressful; the process involves several processes that are critical a very time-consuming. From 
fermentation, purification and harvesting, the methods are time-consuming and very expensive. The 
procedures are usually therapeutic recombinant proteins that are obtained through biotechnological 
process. There is anticipation that in the ten years, 50% of all drugs produced will involve the process 





Nanofiltration and concentration and diafiltration from where the products are primarily harvested. This 
consists in isolating the product from microorganisms, making the product and finding a viable patient, 
putting the product in the patient and learning how the patient reacts to the product, if the product cures 
the particular problem the patient was suffering from, full development is then met, and the product is 
put on sale. The whole process can take from 10-15 years before completion, requiring substantial 
investment. 
Lead identification is one of the vital processes during drug development. The process is also 
called lead optimization. Chemical properties of lead are used in improving potency, pharmacokinetics, 
and selectivity parameters of the developing drug. Once the molecule has been identified, its adsorption, 
distribution, metabolism, excretion and toxicity properties are determined. If the product has no toxicity 
or is not mutagenic, it can be used as a lead molecule.  Therefore, a leading compound or a lead 
compound is a biologically or pharmacological activity is likely to have a therapeutic effect but maybe 
having suboptimal structure requiring a modification that will make it better fit for the target. For a lead 
compound with the developmental focus to be selected, it must be chemically stable and PTMs, be able 
to form solutions and also have physical stability. Chemical stability is in the form of colloidal, 
conformational and interfacial stabilities. Selecting a lead compound that has both the properties of 
functionality and the developmental compound is not easy as the collaborative approach witnessed 
between R and D is very critical for its success. Finally, developmental screening is essential as it 
enables one to select a better drug candidate. This is achieved by identifying molecules that have optimal 
functional and biophysical characteristics and having platforms with compatible leads. Developability 
screening is performed in lead candidates before evaluation of preclinical evaluation. 
In addition to the outlined features, the exquisite specificity of monoclonal antibodies allows 
their application in disease diagnosis and treatment, encountered in both humans and animals. Animals 
are widely employed in the production of monoclonal antibodies. It was established that under adequate 
production conditions, mAb-generating hybridomas are able to survive indefinitely. For this reason, 
continuous production of monoclonal antibodies is associated with reducing the number of required 
animals during in vitro experiments. Nevertheless, despite current advancements in the production of 
monoclonal antibodies, current methods can be highly distressing to host animals, underlying the 
necessity of optimising mAb production technologies (Yamada, et al., 2017, p. 111) (Santos & Galvao, 
2017, p. 696). 
Alfaleh and co-workers describe how mAbs can be effectively generated with the aid of phage 
display technology (Alfaleh, et al., 2017, p. 2). This method of generating mAbs was initially described 
in 1985 by G. Smith (Smith, 1985, p. 1315). Currently, phage display technology is a powerful technique 





protein. It was found that each phage clone corresponding to an antibody phage library displayed a 
specific antigen-binding site. This site was formed by random combinations of both light and heavy 
chain variable fragments, produced through cloning from B-cell pools. A range of binding entities, 
including Fab (Fragment antigen binding), scFv (single-chain variable domain), VL (variable light chain 
regions), VH (Variable heavy chain regions) as well as a series of peptides that could be employed in 
the production of novel biopharmaceuticals were isolated from the described phage display libraries. 
The indicated antibody regions are summarised in the figures 1.2 and 1.3 below: 
 
Figure 1.2: Antibody Fab region. Fragment antigen binding (Fab region) in antibodies, adapted from 
(Merck KGaA, 2015, p. 10) 
 
 
Figure 1.3: Additional antibody structures.  scFv (single-chain variable domain), VL (variable light 







Antibody phage libraries are based on mRNA that was extracted from natural sources, including 
bone marrow, the spleen or peripheral lymphocytes. Alternatively, in order to enhance the required 
properties of antibodies, it is possible to produce the required phage libraries using synthetic methods. 
For instance, combinatorial antibody libraries were produced by using VL- and VH-domains combined 
populations, joined with the aid of protease-resistant (Gly4Ser)3 linkers resulting in the formation of a 
DNA sequence. Comparing various types of displays it was established that monovalent display was 
among the most popular systems due to its ability for selection of antibodies with high affinity (Alfaleh, 
et al., 2017, p. 7). 
Considering recent advancements in this type of technology, it can be stated that antibody 
generation and display utilises a range of new methodologies that harness mammalian and yeast display. 
Literature sources report that a range of various antibodies has been effectively isolated against various 
targets by using yeast display. Also, in addition to the described procedures, mammalian cells were 
employed to display IgGs (Immunoglobulin G) or scFvs, making it possible to isolate high affinity 
antibodies with predetermined biological functions. The various display systems have their own 
advantages and disadvantages, however, a description of every individual system and its areas of 
applications are beyond the goal of this work and the reader is referred to the following for a good 
overview (Farhadfar & Litzow, 2016, p. 14). 
From a manufacturing/production perspective, isolation of various antibody fragments is carried 
out with the aid of panning or affinity enrichment. The purpose of this synthetic technique is to isolate 
mAbs from the corresponding phage library based on the ability of a given mAb to interact with the 
desirable biological target(s). The process consists of three major steps: 1) exposure of the tested library 
to the corresponding target with capturing of the required phage binders; 2) washing of the test solution 
with the purpose of eliminating the presence of low affinity or non-selective binders; 3) elution of 
specific binders with amplification. The described process is repeated from three to six iterations, 
resulting in the overall reduction of the phage diversity along with amplification in the quantity of 
selective binders. The obtained antibodies are subsequently employed in various therapeutic 
applications, such as cancer treatment, autoimmunity and asthma (Ren, et al., 2017, p. 76) (Teo, et al., 
2016, p. 73). 
When considering specific applications of mAbs in modern biotechnology, mAbs are 
extensively employed in the characterisation and classification of tumours and tissues based on the 
expression of defined markers. For instance, implementation of mAbs against various organs associated 
antigens (placental alkaline phosphatase, prostate specific antigen and human chorionic gonadotropin) 
may be employed by pathologists during the identification and characterisation of primary tumours 





structurally similar formations, such as adenocarcinoma and mesothelioma (Ferri, et al., 2016, p. 592). 
These materials are also useful for the identification of tissues or organs where undifferentiated 
metathesis originates. Thus, the detection of metathesis processes through immunocytological analysis 
of tissue samples obtained from bone marrow, lymph nodes as well as other tissues has proven to be 
highly effective by using specific monoclonal antibodies. In cases when axillary lymph nodes are 
investigated for metastatic breast cancer, implementation of monoclonal antibodies to test cytokeratin 
results in the elevation of the detection efficiency by approximately 10% (Ferri, et al., 2016, p. 592). 
In addition to the described above applications of mAbs in cancer treatment, mAbs can also be 
used in the treatment of autoimmune diseases and asthma. Thus, considering the treatment of 
autoimmune conditions, Bruno and co-workers (2011, p.83) indicated that by knowing the 
immunological movements corresponding to autoimmunity, it becomes possible to target all steps of 
the process. In particular, therapeutic applications are focused on activating T lymphocytes in the 
corresponding lymph nodes, the production of immunological synapses, T cell differentiation and 
production of cytokines (Bruno, et al., 2011, p. 283). Finally, monoclonal antibodies may also be 
employed in asthma treatment. As indicated by Byrne (2013, p.23), patients suffering from refractory 
asthma were a considerable burden to the modern system of healthcare. Novel treatment approaches 
presumed the use of humanized monoclonal antibodies or hMabs for the mitigation of the condition. In 
the corresponding publication, Byrne indicated that by using anti-IgE it was possible to considerably 
reduce asthma symptoms in the study group of patients. It was also shown that hMabs were able to block 
IL-5, which was highly beneficial for patients, manifesting in elevated levels of periostin in blood 
(Byrne, 2013, p. 23).  
Monoclonal antibodies are basically distributed cells that are actively divided through the 
biological process of cell division from a single and active ancestral cell. They form a class of antibodies 
with identical off springs of a given hybridoma. In their function, they are very specific in terms of 
location in the human body and are derived from a single biological clone. In addition, the cells can be 
grown indefinitely. Monoclonal antibodies have the ability of recognizing and instantly binding to 
antigens within the human body. The main reason for this process is to actively discriminate between 
specific existing epitopes within the human system responsible for providing protection against disease 
organisms within the human body.  
Monoclonal antibodies function by targeting specific proteins in human system that influences 
cell activities such as receptors. In addition, monoclonal antibodies also target other proteins that exist 
on the surface of both normal and cancer cells. Through their specificity, the antibodies are able to bind 
tightly to cancerous cells. This process is achieved through the help of a cytotoxic agent like a strong 





while at the same time protecting the healthy cells within the human system. This is very critical 
especially when it comes to managing the health of a cancer patient. Most recorded deaths come as a 
result of strong chemo rays that are directed to the area with which the cancer cells have attacked in the 
human body. In the process, many healthy cells are damaged making it difficult from an individual to 
fully recover from the ailment.  
An interesting part of dealing with monoclonal antibodies is tumour cells. There are specific 
tumour cells that display the ability of replicating in an endless manner and are fused with mammalian 
cells that produce specific types of antibodies. The process leads to fusion referred to as hybridoma, an 
action that constantly produces antibodies within the human system. The specific types of antibodies 
that are formed as a result of this process are referred to as monoclonal because they are generated from 
on type of cell. The single cell factor in this case makes it possible to refer to the antibodies that are 
generated as mono. In addition, there are specific types of antibodies that are produced as a result of 
conventional biological methods. These types of cells are then referred to as polyclonal antibodies. They 
are basically derived from a series of preparations that contain many kind of cells and not only one as it 
is for monoclonal cells.  
Monoclonal antibodies are unique in nature based on the manner in which they are produced. In 
this case, they are artificially produced based on a given type of antigen in order to enable the process 
of binding to their target antigens within the human body. There are unique instances where monoclonal 
antibodies are produced in the laboratory. For this case, laboratory production of monoclonal antibodies 
is initiated through clones of a single cell which suggests that every monoclonal antibody in the human 
body is produced by the same human cell.  
Biological fusion of cell culture myeloma cells takes place within the mammalian spleen cells 
antibodies. This process results in hybrid cells that are generally referred to as hybridomas. Hybridoma 
cells have the ability of producing large amounts of monoclonal antibodies which are very crucial in the 
human body when it comes to enhancing protection against infectious diseases. The process of cell 
fusion in this case results in two different types of cells. One of the cells in this case is characterized 
with the ability to grow in a continuous manner. On the other hand, the other cell is characterized with 
the ability of producing large amounts of purified antibodies in the human body. Further research on the 
same suggests that hybrid cells have the ability of producing only 1 exact antibody that is pure in nature 
than any other type of polyclonal antibody. Monoclonal antibodies are more effective in their function 
when compared to conventional types of drugs. These types of drugs have the character of attacking 
foreign substance. They also attack the healthy human cells in the body and for that reason, they have 
certain side effects that may be completely dangerous to use. Side effects would also vary based on the 





Abnormal protein comes as a result of presence of large amounts of specific types of monoclonal 
antibody in the blood. In this case, the protein is detected through physical examination and identified 
via screening blood test referred to as protein electrophoresis. Basically, abnormal production of 
monoclonal antibodies in the human system is considered as a small population of plasma cells that are 
found in large amounts in the bone marrow.  
 
 
Reflecting at the overall process of production of monoclonal antibodies indicates that it is a 
complex cycle. The process involves bulk production of monoclonal antibodies that work against a 
specific type of antigen produced at the same time. In this case, monoclonal antibodies are produced 
through multiple and identical copies of a given type of cell referred earlier as hybridoma. Hybridoma 
in this case is created as a result of fusion of two types of cells. The cells actively combine with 
individual characteristics at hand contributing to the final identity of the product that is generated. 
Therefore, it is critical to understand that formation of each type of cell comes back to the nature of the 
individual cells that initially interacted. It also depends on the type of fusion that took place in order to 
generate a given type of cell. During formation, the formed cells would undergo biological process of 
cell division to generate and spread to other parts of the body. Protection against diseases in the human 





human body is weak in specific organs, the antibodies would be distributed around the area in large 
amounts to ensure that infections that would compromise health of a human being are completely 
addressed before the situation becomes complicated.  
 
1.2 Aims and objectives of the work described in this thesis 
The work described here is aimed at summarising current developments in the area of 
monoclonal antibody therapy and the work undertaken over a period of time by the author in the field 
as evidenced via the publications presented and discussed, specifically describing factors that affect 
stability and integrity of mAb-based formulations destined for use in humans. It is also aimed at 
discussing the findings presented in the published work in the context of the larger field of recent papers 
in the area, their main findings and implications. The contribution of the author here, to each of the 
highlighted publications, is also described.  
The objectives of the work are to: 
1. Provide an introduction to the concept of mAb-based treatment and discuss this therapy in 
relation to other types of treatment. 
2. Give emphasis to the most significant findings in the area of monoclonal antibodies.  
3. Establish fundamental hypothesises between various areas of monoclonal antibody 
development and the corresponding mAb-based formulations. 
4. Outline a possible theoretical framework for the development of monoclonal antibodies-
based formulations using relevant recent publications. 
5. Provide a summary of the key publications submitted by the candidate for consideration 
towards a PhD, the main findings and implications and the contribution of the author to the 
studies. 
1.3 Literature review, including published work by the candidate 
Considering the properties and application areas of monoclinal antibodies described under 
section 1.1 above, it is clear that investigations in the area of mAb formulation stability is of paramount 
importance to the development of novel mAb based drugs. For a protein based medicine, such as a mAb, 
to reach the clinic it must be able to be formulated in an appropriate manner that can maintain the 
stability and activity of the molecule for a specified shelf-life, ensuring its safety, but also so that the 
practitioner can deliver the required dose in an appropriate manner. 
As a general introduction to the concept of monoclonal antibodies as therapies and reagents, it 
can be stated that during the first half of the twentieth century antibody-mediated immunity was 
determined to be fundamentally important for specific immune responses (Merck KGaA, 2015, p. 8). 





improved and antibodies were adopted as critical components in life science research. The main 
principle of all investigations in the area was the fact that specific antibodies would be able to interact 
with specific antigens with the formation of exclusive antibody-antigen complexes. The presented work 
is focused on a range of selected publications, covering various aspects of monoclonal antibody 
formulations, such as characterisation of the corresponding solutions, their stability and the nature of 
chemical interactions between individual peptide molecules. Nevertheless, ScienceDirect indicated that 
the number of publications in the area (Search term: “Monoclonal Antibodies” 1995 – 13.271 
publications - 2017 - 16.203 publications) increased over the past decade what highlighted the 
importance of the topic to the world science (ScienceDirect, 2018). 
The notion antigen presents antibody generation. This term describes any compound that is able 
to produce immune responses, such as generation of specific molecules of antibodies. The definition of 
antigen presumes the possibility of combining with specific antibodies that are generated in its presence. 
In general terms, antigens present foreign proteins as well as their fragments that are introduced in the 
host body through infections. In addition to foreign nature, proteins of various organisms are also able 
to perform the same functions what results in the corresponding autoimmune responses. Viruses and 
bacteria contain antigen molecules on their surfaces and insides. As the consequence, these antigens can 
be chemically isolated for the corresponding development of vaccines. Antibodies are characterised as 
immunoglobulin molecules, capable of specific interactions with antigens. Antibodies are generated as 
a form of response to invasions of foreign molecules. Antibodies are commonly described as 
immunoglobulins (Igs). From the structural perspective human immunoglobulin is similar to 
glycoproteins with 82-96% forms by proteins and the remaining part by carbohydrates (Merck KGaA, 
2015, p. 9). These molecules are of paramount importance to human immunity, what underlines the 
necessity of investigations in the area. 
Detailed description of all recent publications in the area is beyond the goal of the work, however 
it is clear that effective purification of the corresponding monoclonal antibodies is fundamentally 
important to any type of research in the area. Thus, Yamada and co-workers described an efficient flow-
through mode of monoclonal antibody purification (Yamada, et al., 2017, p. 110). The research group 
indicated that employed in various biopharmaceutical applications, such as production of new drugs and 
modification of the existing ones. It was found that buffer exchanges would be able to substantially 
improve impurities removal during depth filtration. Yamada and co-workers demonstrated that by using 
various depth filters it was possible to obtain the necessary level of protein purification. Based on the 
obtained results, a flow-through operation mode was suggested as an effective antibody manufacturing 
process (Yamada, et al., 2017, p. 110). The following sections of the review are focused on selected 





characterisation of the corresponding formulations. Protein formulation is a vital component in 
biological development. Formulation of proteins entails of conducting a series preformation trials to 
determine the solubility at various ionic strengths or pH conditions. After establishing the solubility 
properties, conduct the new iteration to test the pH conditions, salts, ionic strengths and buffering agents. 
This is followed by performing ability screening approach to enable selection of optimal conditions by 
use of proprietary formulation development technique.  Stability of proteins refers to the net balance of 
forces, which determine whether proteins are in their denatured or native folded stage.  Interactions 
between disulphide, Van der Waals, hydrophobic, hydrogen bonding and electrostatics are factors that 
determine stability of proteins. Denatured state of proteins is characterised by entropic and non-entropic 
free energies. 
 
1.3.1 General Approach to Formulation of Biotherapeutic Proteins, Particularly mAbs 
The formulation of mAbs can be considered from the perspective of a standard manufacturing 
process, using mammalian cell culture (Li and Amanullah, 2010, p.2). Cells are grown in culture over a 
period of weeks to provide a seed culture (also called inoculum) for fermentation (Vazquez-Rey and 
Lang, 2011, p.1495). Subsequent culture techniques lead to dramatic expansion of the cell population 
and culminate in cell harvesting through centrifugation or microfiltration methods. The following stage 
involves ‘capturing’ the protein, using chromatography (Protein A or ion exchange), often combined 
with additional purification stages to remove host proteins and other impurities, including a stage of 
membrane filtration and nanofiltration (Bee et al., 2009, p.940). During this process, there is an 
important emphasis on the conditions used to generate cells, as well as during the analysis and 
purification of proteins, including mAbs, captured from these cells. 
Under standard biological condition in vivo, the cellular and extracellular environment is tightly 
regulated through a diverse range of homeostatic mechanisms (Vazquez-Rey and Lang, 2011, p.1495). 
The regulation of factors such as pH, temperature, and ionic concentrations provides the basis for 
creating a biologically stable environment for a range of biological activities, including the formation 
and processing of proteins (Wang et al., 2007, p.2). As deviations in any of these parameters may render 
proteins unstable or dysfunctional it is necessary to consider the effects of the environment when 
formulating proteins ex vivo and in pharmaceutical or biomedical contexts.  
One of the most concerning aspects of protein formulation is the potential for aggregation 
(oligomerisation) of proteins, which was first described in the Lumry-Eyring model (1954). Aggregation 
events are commonplace, although the underlying mechanisms for aggregation are not completely 
understood in all drug manufacturing contexts. Adding to the complexity of understanding these 





aggregates, covalent/non-covalent aggregates, native/denatured aggregates, and reversible/non-
reversible aggregates (Wang et al., 2007, p.6). It is beyond the scope of this paper to consider the aspects 
of formulation associated with all of these aggregation definitions. However, it is apparent that 
aggregation removal and/or control is essential to ensure the biological activity of the resulting proteins 
(including mAbs) and to ensure no harmful effects occur in the recipient of the drug due to the effects 
of aggregates (Vazquez-Rey and Lang, 2011, p.1497).  
Aggregation during the production of mAbs may occur at multiple stages, providing a basis for 
tight regulation of the formulation process throughout the production of mAbs. Aggregation can occur 
during initial cell culture, both within the cell and following secretion of the protein in the cell culture 
medium (Vazquez-Rey and Lang, 2011, p.1497). A large amount of aggregation also occurs during the 
purification process of mAb production, whereby the environmental characteristics of the process have 
a particularly important effect on aggregation potential (Iacob et al., 2013, p.4316). Modulation and 
control of the environment, including the addition of excipients to stabilise proteins again aggregation 
and denaturation, is commonplace in biomedical manufacturing as a consequence (Iacob et al., 2013, 
p.4316).  
The remainder of this section will consider the excipients used for protein stability and 
formulation, with a specific focus on excipients relevant to mAb formulation. These excipients include: 
pH and buffering agents, salts, sugars, amino acids, and surfactants.   
 
1.3.2 Excipients in mAb formulation 
 
1.3.2.1 pH and buffer characteristics 
Buffer solutions are used throughout the process of mAb manufacturing and can have complex 
effects on the stability of proteins (Cleland et al., 1993, p.307). Aggregation of mAbs has been 
associated with interactions between the Fc domain of immunoglobulins (Igs), particularly IgG (Wang 
et al., 2007, p.7), while it has also been noted that some buffers have little or no effect on protein stability 
(Daugherty and Mrsny, 2006, p.700). The purpose of buffers is to provide some regulation over the 
solution pH, among other characteristics, as pH is considered an important determinant of protein 
formulation, stability and ultimate function (Vazquez-Rey and Lang, 2011, p.1497).  
The effect of pH influences the ionic features of the protein molecule, which can influence 
protein-protein interactions, the three-dimensional conformation of the protein structure, and the 
interaction of the protein with other molecules (Zheng and Janis, 2006, p.47). Carboxyl groups and 





values close to the isoelectric point (pI) of the protein can lead to the formation of diploes (Wang et al., 
2007, p.14). The pI is achieved when the protein exhibits equal positive and negative charge in the 
carboxyl and amino groups, which promotes the degree of interaction between proteins (Zheng and 
Janis, 2006, p.49). Therefore, when the pH is close to the pI of the protein, aggregation is more likely 
to occur. The formulation of mAbs is typically performed with pH values lower than the pI, leading to 
disruption of the dipole state and the generation of a clear overall charge on the protein molecule (Liu 
et al., 2008, p.2427). Consequently, protein monomers are more likely to repel each other (due to 
identical electrostatic charges), making aggregation a less energetically favourable process (Wang et al., 
2007, p.15). Therefore, regulation of pH in order to reduce aggregation is an important aspect of mAb 




As with the pH of a solution, the importance of buffer characteristics is also evident in 
determining the effects of salts on protein stability (Shire et al., 2004, p.1392). Salt ions can interact 
with proteins in a number of ways and to varying degrees, depending on the overall pH of the solution 
and the types of salts present in the buffer/solution. Salts form a large amount of the ionic strength of 
the solution and the use of polyvalent salts in particular has the potential to promote aggregation through 
an increase in ionic strength of the solution (Ohtake et al., 2011, p.1055). When ionic strength of the 
solution is increased due to the dissolution of salts with high valence, ionic accumulation adjacent to the 
surface of proteins is common (Ohtake et al., 2011, p.1055). This leads to an increase in the potential 
interactions between proteins and subsequent aggregation, due to presence of counter-charged salt ions 
close to the protein surface. The use of trivalent, bivalent or monovalent salts may reduce the potential 
for aggregation.  
High concentrations of salts can also act to stabilise protein formulations through a mechanism 
of preferential exclusion (Vazquez-Rey and Lang, 2011, p.1498). Preferential exclusion refers to the 
deficiency of co-solvent molecules in the vicinity of the protein/mAb and is also termed preferential 
hydration, as water molecules dominate the region around the protein molecule (Arakawa et al., 1991, 
p.287). The result of preferential exclusion is that protein stability increases, and solubility decreases 
due to the energetically unfavourable nature of salt-protein interactions and the stable conformation of 
the protein as a consequence (Vazquez-Rey and Lang, 2011, p.1498). Different anions have a different 
effect on precipitating out proteins and have been classified according to the Hofmeister series, which 









Sugars may also be used to stabilise proteins, specifically sugars that are non-reducing, including 
sucrose and trehalose (Wang, 1999, p.133). The use of reducing sugars is not considered suitable in 
biomedical protein stabilisation due to the potential for the Maillard reaction (amino acid deprotonation) 
(Wang, 1999, p.133). However, non-reducing sugars have been shown to reduce the activation energy 
of protein unfolding, with stability in proteins induced through preferential exclusion (Daugherty and 
Mrsny, 2006, p.688). For the stabilisation of mAb proteins during freeze-drying, sugars and polyols may 
act by stabilising protein kinematics within a matrix or by acting as water substitutes, maintaining 
thermodynamic stabilisation in the place of water molecules lost during the freeze-drying process.  
 
1.3.2.4. Amino acids 
The role of amino acids in the stabilisation of proteins has been recognised for many decades, 
although the precise mechanism of this stabilising effect is a matter of on-going debate, while varying 
to some extent between the use of different specific amino acids (Frokjaer and Otzen, 2005, p.298). 
However, there is a general suggestion in the literature that amino acids stabilise protein formulations 
by interfering with protein-water interactions and adjusting the thermodynamic properties of the 
medium (Wang et al., 2007, p.14). The use of arginine (Arg) and glutamic acid/glutamate (Glu) is 
common in the context of drug manufacturing and protein stabilisation for biomedical purposes 
(Golovanov et al., 2004, p.8935). These amino acids have been shown to stabilise the thermodynamic 
properties of protein-water interactions, reducing the potential for aggregation and enhancing stability 
in solution (Frokjaer and Otzen, 2005, p.298). However, the precise mechanisms of these amino acids 
will be considered later in this paper.  
 
1.3.2.5 Surfactants 
The use of surfactants in the stabilisation of proteins is also commonplace and is particularly 
important where formulation involves stages such as mixing, shaking or repeated freeze-thaw cycles 
(Kerwin, 2008, p.2924). Surfactants (e.g. polysorbate 80) reduce the tension in the air-water interface, 





unfolding and aggregation (Kerwin, 2008, p.2924). Surfactants may act in numerous ways to promote 
mAb stability, including through competition with the protein at the air-water interface, shielding of 
hydrophobic regions of the protein, or serving as a chaperone for protein folding (Wang et al., 2007, 
p.17). 
The following sections contain a brief introduction as to the rationale for each of the publications 
discussed in this submission in more detail. 
 
1.3.3 Paper 1: Kheddo P, Cliff MJ, Uddin S, van der Walle CF, Golovanov AP (2016) Characterizing monoclonal 
antibody formulations in arginine glutamate solutions using 1H NMR spectroscopy, MAbs 8(7):1245-1245. 
The characterisation of various mAb-based formulations, and the impact of the formulations on 
the mAb, was undertaken by H1 NMR as part of one of the publications submitted by the candidate for 
consideration within this thesis submission (Kheddo, et al., 2016, p. 1245). The necessity of the research 
described is supported by the fact that monoclonal antibodies are heavily utilised as biotherapeutics and 
as reagents in a substantial number of clinical investigations. However, it was established that increasing 
therapeutic concentrations of monoclonal antibodies increases self-association and aggregation of 
proteins, thus promoting their instability. In addition to the outlined negative effects it is expected that 
elevated therapeutic protein concentrations will result in the formation of soluble clusters that, in turn, 
may have a negative impact on the viscosity of the corresponding formulations. The outlined negative 
effects generally take place at protein concentrations >100 mg/ml and it was hypothesised that the 
addition of excipients should be considered, and able, to minimise such undesired instability (Kheddo, 
et al., 2016, p. 1245).  
After analysing recent developments in the area of excipient formulations, it was established that 
arginine glutamate was effective and safe for routine implementation in the design of new formulations 
(Kheddo, et al., 2014, p. 127). Arginine has been shown to protect proteins against aggregation by 
slowing protein-protein association reactions and protein folding (Baynes et al., 2005, p. 4919).  
However, when combined with glutamate (glutamic acid), the Arg-Glu effect is synergistic and provides 
a stronger reduction in intermolecular interactions and subsequent aggregation compared to Arg alone 
(Vedadi et al., 2006: 15835). As a result of the study by Kheddo et al., (2014, p.127), it was expected 
that new synergistically working excipients would and could be developed in order to improve stability 
of novel monoclonal antibody-based reagents and drugs. However, in order to estimate mAb self-
association that may take place at elevated protein concentrations, novel orthogonal analytical 
techniques are necessary. Currently, sample dilution is necessary to effectively carry out protein 
characterisation by standard analysis methods (e.g. mass spectrometry, chromatography, dynamic light 
scattering), thus orthogonal analytical techniques are required that allow the user to monitor changes in 





sample dilution, at the formulated concentration and ambient temperature. Sample dilution results in 
concentration changes that will alter protein-protein interactions, self-association and stability of the 
molecule in question. Dilution of protein samples presents an intrinsic component of sample preparation 
for NMR investigations. The potential primary impact of the sample preparation procedure is to avoid 
slow protein precipitation, formation of a mixture containing both folded and unfolded proteins, reduce 
aggregation problems and degradation. It is clear that with the aid of sample dilution it is possible to 
produce uniform solutions, containing the same configurations of protein molecules (Cavanagh, et al., 
2006, p. 76). Kheddo and co-workers indicated that by investigating the corresponding protein-based 
drugs at their target concentrations, it should be possible to establish the most effective stabilising agent 
(Kheddo, et al., 2016, p. 1246).  
Kheddo and co-workers demonstrated that NMR spectroscopy was a powerful but underutilised 
approach in the analysis of mAb-based formulations (Kheddo, et al., 2016, p. 1246). It was suggested 
that when NMR was applied to the analysis of proteins it was possible to quickly and efficiently monitor 
signal changes as the result of functional group dynamics in solutions (Cavanagh, et al., 2006, p. 77). 
Nevertheless, while applying NMR to solutions containing monoclonal antibodies, broad and 
overlapping signals were observed. The indicated observation is associated with the large molecular 
sizes of the investigated mAbs (approx. 145 kDa) and complex interactions between various molecular 
groups. Further, traditional analysis techniques associated with NMR analysis, such as isotopic 
labelling, could not be applied to these systems due to production difficulties in natural systems. 
Nevertheless, characterisation was possible under elevated temperatures, which resulted in reduced 
water viscosity, allowing formation of proton NMR spectrum with distinguishable signals, 
corresponding to different function groups of the protein. Kheddo and co-workers show that common 
NMR-detectable parameters including signal intensities, deuterium exchange rates, relaxation times as 
well as rotational and translational diffusion were heavily depended on protein stability, aggregation 
and self-association in the corresponding tested solution (Kheddo, et al., 2016, p. 1246). This reinforces 
the need to be able to investigate formulations without diluting the samples beforehand to understand 
their behaviour under the concentrations at which they will be formulated. The results of this study are 


































































1.3.4 Paper 2: Kheddo, P., Golovanov, A. P., Mellody, K. T., Uddin, S., van der Walle, C. F., & Dearman, R. J. 
(2016). The effects of arginine glutamate, a promising excipient for protein formulation, on cell viability: 
Comparisons with NaCl. Toxicology in Vitro, 33: 88-98. 
The importance of stabilising monoclonal antibodies-based formulations was outlined in a 
further publication by Kheddo and co-workers (Kheddo, et al., 2016, p. 88). This study established that 
the mAb product must have an adequate shelf-life under common shipping conditions and storage 
temperatures. Currently, by changing pH and ionic strength of the mAb solution, it is possible to change 
the necessary stability parameters, however more recently a particular focus has been placed on the 
possibility of adding various excipients (Watts, et al., 2005, p. 521). These compounds were found to 
substantially increase product stability through prevention of aggregation as well as enhanced protein 
optimisation in the corresponding pharmaceutical products. Stabilising compounds include glycine, 
histidine, arginine as well as other amino acids. In addition to the indicated excipients, sugars were also 
found to provide a stabilising effect. A range of theories is suggested to explain the observed protein 
stabilisation in the presence of these excipients. These theories include prevention of protein aggregation 
through excluded volume as well as preferential interactions and hydration (Bye, et al., 2014, p. 869). 
Selection of excipients in the industrial settings in carried out using biophysical assays where a range of 
possible candidates is initially identified and screened to compare the impact of these on the product 
stability. 
When comparing the stabilising effects of various excipients, Arakawa and co-workers found 
that arginine was particularly effective in supressing aggregation of proteins (Arakawa, et al., 2007, p. 
2). The exact mechanism of action was not established, however it was determined that arginine was 
able to form reversible bonds with protein side chains that was compensated by repulsion from other 
chains and groups (Arakawa, et al., 2007, p. 3). The concentration of arginine determines the total 
stabilisation effect and the difference between repulsion/attraction that is observed upon producing 
arginine-stabilised products. Computer based simulations suggested that arginine cations produce 
clusters at certain protein regions, rich with carboxylate and guanidinium side chains. It was also 
established that stabilisation was substantially affected by the presence of ion-ion pairs as well as other 
charged groups. Thus, it was found that arginine citrate, phosphate and sulphate were the most active 
forms of arginine with the strongest aggregation suppression effect.  
In addition to arginine and arginine-based salts, the possibility of using other amino acids in 
protein stabilisation was explored. Thus, equimolar mixtures of arginine and glutamate were prepared, 
and their stabilisation properties tested. The described amino acids are intrinsic components of cells, 
they can be found in the diet of both humans and animals. For this reason, arginine and 
arginine/glutamate-based excipients present a highly attractive stabilising component of monoclonal 





antibody stabilisation with arginine-based excipients indicated that it was possible to achieve solution 
stabilisation under elevated temperatures and broad pH range (Kheddo, et al., 2016, p. 89). The results 















































1.3.5 Paper 3: Hamrang, Z., Hussain, M., Tingey, K., Tracka, M., Casas‐Finet, J. R., Uddin, S., et al. (2015). 
Characterisation of stress‐Induced aggregate size distributions and morphological changes of a Bi‐Specific 
antibody using orthogonal techniques. Journal of Pharmaceutical Sciences, 104(8): 2473-2481. 
In addition to NMR based techniques, reports in the area suggest that orthogonal methods (e.g. 
such as Dynamic Light Scattering (DLS), Micro-Flow Imaging (MFI), Raster Image Correlation 
Spectroscopy (RICS)) could also be used for characterisation of monoclonal antibodies and the 
corresponding mAb-based formulations (Hamrang, et al., 2015, p. 2473). As described in the sections 
above, stabilisation of mAb drugs is of paramount importance to the development of safe and effective 
formulations. Kheddo and co-workers indicated that protein self-association and aggregation may be 
observed under physiological conditions, however in the work by Hamrang and co-workers it was 
indicated that various stress (changes in temperature, pH, addition of buffers) conditions might result in 
the formation of protein aggregates characterised by different formation mechanisms and morphologies 
(Hamrang, et al., 2015, p. 2474). For instance, it was described that freeze-thaw can result in partial 
protein unfolding as a result of changes in cryo-concentration of the tested solutes and pH changes, 
observed as the result of buffer crystallisation. In addition to the described experimental conditions, 
increased temperatures may also have a negative impact on conformational changes in the investigated 
proteins. Thus, a gradual increase in temperature may result in protein unfolding which, in turn, may 
trigger additional partial unfolding of different areas of the protein molecule. The outlined processes 
mediate conformational changes, which promote aggregation as described in the manuscript (Hamrang, 
et al., 2015, p. 2475). The results of this study are discussed in section 3.2 below. 
Recent publications indicated that during particle characterisation more emphasis should be 
placed on the determination of particles in the 0.5-5 µm range, due to possible production of novel 
pharmaceuticals. Aggregates in this size range can be classified as sub-visible and novel characterisation 
methods should be developed to characterise particles in this size range. Currently, the majority of 
experimental challenges encountered during the analysis of protein aggregates are associated with the 
inability of the employed techniques to characterise a considerable range of particles sizes and 
discriminate between foreign/protein-based particles (Hamrang, et al., 2015, p. 2476). Modern 
analytical methods that are employed in the characterisation of various aggregates are graphically 







Figure 1.4: Modern analytical methods employed in particle characterisation and the range of sizes 
over which these can be used to measure particles, adapted from (Hamrang, et al., 2015, p. 2474). 
MALLS refers to multi-angle laser light scattering technique, FFF refers to field-flow fractionation, 
AUC is analytical ultracentrifugation, CE-SDS is capillary electrophoresis-sodium dodecyl sulphate 
and SEC is size exclusion chromatography (Hamrang, et al., 2015, p. 2474). 
 
Figure 1.4 suggests that multiple methods can be applied to characterise protein particles of the 
same size, however in all cases a lack of discrepancy of the methods to differentiate between protein-
based particles and foreign contaminants presents a considerable disadvantage. It can also be observed 
that possible characterisation methods may fundamentally employ different characterisation principles, 
but the outlined above disadvantages will be intrinsic to all of the applied techniques. In figure 1.4 
above, analysis methods marked with an asterisk represent techniques that are unable to perform 
quantification of particle size absolute distributions. 
Taking into consideration the outlined above disadvantages associated with traditional analysis 
techniques and the importance of preventing protein aggregation that was discussed in publications by 
Kheddo and co-workers, the development and use of alternative analysis methods needs to be 
investigated. In particular, Hamrang and co-workers suggested that implementation of RICS (Raster 
Image Correlation Spectroscopy) can be highly effective in the analysis of particle morphology 
(Hamrang, et al., 2015, p. 2475). The same research group also indicated that by combining RICS with 
other analytical techniques, such as DLS (Dynamic light scattering) and MFI (micro-flow imaging) it 
was possible to analyse particles across a considerable size range that were generated as the result of 
freeze-thaw and thermal stresses. Literature sources indicate that RICS is a well-established analytical 
tool, that has been employed in various situations to measure particle mobility and size through the 





From a practical perspective, during the collection of confocal fluorescent images, intensity of 
fluorescence gradually changes due to diffusion of the analysed molecules across the corresponding 
confocal volume and subsequent recording of the produced raster scan. In turn, particle size and yield 
information can be produced based on correlations between fluctuations of fluorescence intensities, 
observed within confocal data. It is clear that the described methods can be employed in conjunction 
with the technique developed by Kheddo and co-workers to investigate particle size distributions in 
monoclonal antibody-based formulations (Kheddo, et al., 2016, p. 89). 













































1.3.6 Paper 4: Gonçalves, A. D., Alexander, C., Roberts, C. J., Spain, S. G., Uddin, S., & Allen, S. (2016). The effect 
of protein concentration on the viscosity of a recombinant albumin solution formulation. RSC Advances, 6(18): 
15143-15154. 
Recent publications describe a range of theories that have been developed to describe processes 
taking place in solutions with increases in macromolecular content (Goncalves, et al., 2013, p. 1). For 
instance, a range of theories are based on a presumption that protein molecules behave as hard spherical 
repulsive particles, however instances of successful applications are limited. Thus, it was determined 
that in addition to molecular shapes and volumes, additional properties such as association kinetics and 
charge distribution must be taken into consideration in order to accurately predict behaviour of proteins 
in solutions and estimate viscosity. In addition to the above factors, introduction of additives as well as 
changes in the pH of the solution and its ionic strength was found to affect production of oligomeric 
species. This issue is of paramount importance because it was established that viscosity of protein-based 
formulations substantially affected the biopharmaceutical industry in general and 
manufacturing/administration of pharmaceutical products in particular. In a considerable number of 
cases production of protein-based drugs involves generation of highly concentrated protein 
formulations. The necessity of these procedures is determined by cost reduction requirements and the 
need to deliver high concentrations of the active component using low volumes of the generated 
pharmaceutical product. However, elevated concentrations of bio-macromolecules in many cases are 
associated with poor processing of the material, caused by elevated viscosity and lack of adequate flow 
abilities (Goncalves, et al., 2013, p. 2). 
Loveday and co-workers extensively described the correlation between solution viscosity and 
protein concentration (Loveday, et al., 2007, p. R101). When the concentration of proteins is low it is 
possible to study protein viscosity in solutions using models that are focused on the hydrodynamic 
behaviour of the studied protein. In addition to hydrodynamic based theories a range of other concepts 
were implemented to describe the behaviour of proteins in solutions and predict changes in viscosity 
using protein concentration. However, regardless of the implemented model it is assumed that proteins 
in solutions are hard macromolecular spheres and an increase in concentration correlates with an 
increase in viscosity.  
The number of studies covering a broad range of protein concentrations as well as possible 
correlations between high protein quantities and viscosity is however, limited. Publications in the area 
describe changes in viscosity of protein solutions through the perspective of intrinsic viscosity. Intrinsic 
viscosity presents a hydrodynamic parameter that is dependent on the size of the molecule and its 
conformation. This parameter also presents the effective molecular volume under the specific analysed 
conditions. The hydrodynamic parameter can be calculated by using the Ross-Minton’s approach or 





model it is assumed that all changes in the protein composition in the analysed solution are negligible. 
A considerable disadvantage of the employed models is the fact that protein species in solutions are 
assumed to be uniform with specific size and shape. In order to address this disadvantage binary 
mixtures were employed, containing proteins of various sizes. With the aid of the developed models it 
became possible to more accurately predict the behaviour of protein molecules in solutions. Further, 
recent publications suggest that it was highly effective to estimate the behaviour of protein species in 
solutions by using controlled quantities of binary protein mixtures in solutions and determination of the 
resulting viscosity (Goncalves, et al., 2013, p. 3). 
Goncalves and co-workers explored the effects that changes in protein concentration had on 
viscosity in various formulations of recombinant albumin. The conducted study investigated changes in 
the human serum albumin concentrations from 0.1 to 500 mg/mL. The corresponding human albumin 
solutions were prepared in a salt-based buffer. Human serum albumin is the most abundant protein that 
can be found in the human blood. Its concentration is approximately 40 mg/mL and the function of the 
protein is to transport active pharmaceutical compounds and unesterified fatty acids. The research group 
showed that by taking into consideration specific biophysical characteristics of the analysed protein, 
such as shape and size, it was possible to estimate aggregation patterns of protein species and viscosity 
of the overall solution. It was also showed that viscosity of protein solutions could be predicted at both 
high and low protein concentrations. Thus, correlations between protein structure, its concentration in 
solution and viscosity could subsequently be employed in the development of new pharmaceutical 
















































































1.3.7 Paper 5: Ouberai, M.M., Dos Santos, A.L.G., Kinna, S., Madalli, S., Hornigold, D.C., Baker, D., Naylor, J., 
Sheldrake, L., Corkill, D.J., Hood, J. and Vicini, P., 2017. Controlling the bioactivity of a peptide hormone in vivo 
by reversible self-assembly. Nature Communications, 8(1), p.1026. 
Using peptides as therapeutic agents are undergoing research with expectations to discover a 
new drug that has enhanced levels of efficacy and safety. Peptides full capabilities and potentials will 
only be understood only if their physiochemical and pharmacokinetics are clearly understood. The 
research paper is on how a self-assembly strategy for peptides can be used to control and even prolong 
the bioactivity of another natural peptide hormone in vivo. Having high potency and specificity and also 
safety structure, peptides are unique and have the potential for the development of therapeutic agents. It 
is, however challenging as the number of peptides in the market has low solubility, aggregation 
propensity, chemical instability, little stability against high clearance and short duration of in vivo 
activity. There are several ways of improving peptide bioavailability with one being engineering peptide 
analogs that contain unnatural amino acids and conjugate them to polymers, fatty acids, or other 
abundant proteins. Since the subcutaneous injection is one of the most common ways through which 
most peptides are administered, there is need to reduce a frequency of dose, have accurate deliver and 
achieve consistency while applying and these requirements are vital in and needs to be adhered to during 
treatment where one wants to make and manage chronic diseases effectively. Another different way of 
approaching the drawbacks, as stated above, would be employing processes that occur naturally like 
supramolecular self-assembly. The means are solely based on the idea that polypeptide chains align 
themselves into o β-sheet abundant amyloid-like fibrils. 
The Oxi (oxyntomodulin) peptide hormone has been tested as a treatment of obesity by reducing 
the amount of food ingested increasing energy used in both humans and rodents. Local Oxm is capable 
of achieving weight loss and glucose control simultaneously, thereby being a suitable agent for the 
treatment of both diabetes and obesity. Oxfam has a short elimination half-life of 12 minutes in humans, 
a drawback currently being foreseen by engineers. 
Based on this inference, the wide utilization of self-assembling nanofibrils still requires evidence 
of inclination of natural peptides to be formulated as self-assembling nanostructures (reversibly). 
Oxm is capable of self-assembly into nanofibrils since it has 29amino acid glucagon sequence 
under serene conditions into nanofibrils which dissociate releasing active peptide under physiological 
states. It is also evident that Oxm administration in mice produces the pharmacological glucose-lowering 
effect. With these studies, it is an apparent reduction of dose frequency via reversible self-assembly 
plays a vital role in the treatment of chronic diseases like diabetes and obesity. 
Oxi under high yield and mild state can be converted into fibrillary nanostructures estimated at 





Oxm nanofibrils when incubated under five different media dissociated releasing intact 
peptide. Electrostatic interactions proved to have a significant impact on the stability of fibrillar Oxm. 
The different states on equilibrium are hence attained concerning the countries of the solution such as 
pH, peptide concentration and the various salts available.  The full dissociation of glucagon fibrils 
given time, happen under high dilution. 
From the results obtained, it is evident that self-assembled peptide has the capability of 
releasing helical conformation like peptides which is a crucial fundamental element necessary for cell 
receptor activation. 
DPI (dual polarization interferometry), a technique employed in the dissociation profile of 
Oxm nanofibrils, was used in the characterization of the dissociation process of the nanostructures in 
conditions emulating the s.c. Compartment. However, contrary to amyloid-like fibrils known for their 
stability under several solution conditions, Oxm nanofibrils (under physiological conditions in PBS) 
dissociate. 
The chemically-stable peptide released is found to be active and nontoxic in vitro. In 
physiological conditions, Oxm can be used as a reservoir where active peptides are kept stored and 
released with dissociation of nanofibrils. This proves that fibrils in their maturity stage are nontoxic 
reservoirs of polypeptides and non-fibrillar oligomeric assemblies being toxic. 
Oxm nanofibrils, when laced in vivo, produced an effect that lowered glucose level. 
Furthermore, Oxm when dosed in vivo presented prolonged serum bioactivity. With our study, it is 
evident that peptide hormones like the Oxm self-assemble in a reverse manner. The data acquired had 
an inference that Oxm formulation of nanofibril produces an effect of lowering the glucose level. With 
this data, we are provided with a fundamental basis under which we can create a more in-depth 
understanding of the possible merits of nanofibril formulation. To improve on the serum stability of 
the peptide, there would have to be binding of self-assembling nanostructures discretely.  
The balance between monomeric and fibrillary states can be managed by enhancing self-
assembly conditions to give a more precise fibril structure and peptide confirmation with the 
corresponding improvement in vivo performance of fibril formulation. The study makes it possible for 
a concise assessment of the clinical application of self-assembling (reversible) Nano fibrils. 
Finally, we can employ this strategy to other peptides to self-assemble into nanostructures, 











































1.3.8 Paper 6: Zapadka, K. L., Becher, F. J., Uddin, S., Varley, P. G., Bishop, S., Gomes dos Santos, A. L., & Jackson, 
S. E. (2016). A pH-induced switch in human glucagon-like peptide-1 aggregation kinetics. Journal of the 
American Chemical Society, 138(50): 16259-16265. 
As discussed above, protein aggregation is a potentially widespread phenomenon with a range 
of implications in various pharmaceutical and biomedical applications. Consequently, by better 
understanding the exact mechanism of aggregation it may be possible to develop new, more stable 
protein based-drugs with higher therapeutic activities. Zapadka and co-workers indicated that in addition 
to aggregation, formation of amyloid fibril was also an important factor that contributed to structural 
changes and loss of properties of peptide-based formulations (Zapadka, et al., 2016, p. 1). The research 
group indicated that the aggregation of proteins and peptides into amyloid fibrils rich with beta-sheets 
was a common transformation process that could be observed in peptide containing solutions. The 
formation of these structures substantially reduced the effectiveness of various pharmaceutical products 
and contributed to yield reduction in the development of new drugs. A considerable number of research 
efforts were focused on better understanding of the underlying mechanisms resulting in the formation 
of such amyloid fibrils for specific proteins, however the overall level of understanding remains low. 
Nevertheless, it was established that agglomeration of proteins as well as formation of amyloid-fibrils 
proceeded via sigmoidal-like kinetics characterised by a nucleation-polymerisation mechanism. The 
process was also characterised by the presence of a lag phase during which formation of nucleating 
species was observed. This lag phase was subsequently followed by a phase of rapid growth with the 
formation of a plateau in cases where the system reaches equilibrium. Chiti and Dobson indicated that 
formation of oligomers at low concentrations was also possible along with the formation of fibrils (Chiti 
& Dobson, 2006, p. 333). A considerable amount of progress was made in describing factors that affect 
system aggregation. Key factors included internal parameters such as molecular volume, ionic strength, 
pH, concentration and conformation of monomer and rate of nucleation. Other highly important factors 
included agitation and changes in temperature. The number of factors that affect formation of oligomers 
is not limited to those outlined above which highlights the necessity of additional investigations in the 
area (Zapadka, et al., 2016, p. 2). 
Zapadka and co-workers have described how human glucagon-like peptide-1 or GLP-1 is an 
important biopharmaceutical product. This peptide has found a range of applications in the drug industry 
in the development of type-2 diabetes drugs. Buell, Dobson and Knowles suggest that formation of 
GLP-1 based aggregates with the formation of amyloid fibrils occurs at acidic pH and physiological 
conditions (Buell, et al., 2014, p. 11). From a structural perspective, GLP-1 presents a hormone peptide, 
containing 31 amino acid residues. The peptide regulates glucose levels in blood through glucose-
dependent secretion of insulin. In turn, structural changes in the peptide as well as the impact that pH 





CD (far-UV circular dichroism), SEC (size-exclusion chromatography), DLS (Dynamic light 
scattering), MALS (Multiangle light scattering detector) and analytical ultracentrifugation (AUC). 
Changes in the protein structure as well as its stability and fibrils morphology may be confirmed by 
using other instrumental techniques including TEM (Transmission Electron Microscopy) and AFM 
(Atomic Force Microscopy) (Zapadka, et al., 2016, p. 2). 
Aggregation kinetics of GLP-1 at various pH were described in the publication by Zapadka and 
co-workers (Zapadka, et al., 2016, p. 2). The report explains how experimental data could be obtained 
by using thioflavin T based monitoring of fluorescence. This reagent was shown to increase its 
fluorescence levels upon forming bonds with beta-sheets of amyloid fibrils. Analysis of the resulting 
experimental data was focused on the determination of the apparent growth rate as well as lag time that 
was associated with different concentrations of the peptide and pH. During the conducted experiments 
it was established that pH had a considerable impact on the overall aggregation kinetics. The research 
group indicated that the observed results did not correlate with other kinetics patterns, established in the 
case of similar proteins (Zapadka, et al., 2016, p. 2). Thus, it was established that at pH 8.5 the observed 
aggregation kinetics could be explained with the aid of a nucleation/polymerisation fibril formation 
mechanism, however at pH 7.5 it was observed that increases in the peptide concentration were 
associated with increase in the lag time of aggregation. The obtained results can be explained by the 
formation of additional intermediary species and oligomers through slow uni-molecular pathways. Both 
the structure and stability of the corresponding intermediary formations as well as the initial point of the 
aggregation process can be established using the indicated methods of analysis. Comparing the obtained 
findings with the previously discussed publications, a range of factors influence the behaviour of 
proteins in solutions and the impact of each factor is dependent on the structure of the analysed protein 
or peptide. The process of aggregation involves formation of various intermediary species what may 
reduce the area of potential applications of the analysed peptides (Zapadka, et al., 2016, p. 3). The results 








































The key results from each publication submitted for consideration under this thesis are described 
below. 
 
3.1 Application of NMR spectroscopy in characterisation of monoclonal antibodies 
Kheddo and co-workers applied the methods described in the previous sections based on proton 
NMR spectroscopy to characterise formulations containing monoclonal antibodies in arginine 
glutamate-based solutions (Kheddo, et al., 2014, p. 1246). Thus, in the first section of the experimental 
work it was required to use one dimensional proton NMR spectroscopy to establish stability of 
monoclonal antibodies with the addition of arginine glutamate. The results obtained by the research 
group are summarised on the figure 3.1 below: 
 
Figure 3.1: Correlation between the addition of arginine glutamate and NMR signals of monoclonal 
antibodies, adapted from (Kheddo, et al., 2016, p. 1246). 
 
In figure 3.1 above, slides A-G represent selected regions of proton NMR spectra of monoclonal 
antibodies at tow pH values with corresponding concentrations of components. In cases A-F CP (10 
mM) buffer was used to produce the corresponding solutions. For comparison purposes, panel G 





glutamate. Dependencies between intensities of the recorded peaks and corresponding viscosity of the 
tested solutions are represented in figures H-N, figure 3.1. Trends represented in figure 3.1 indicated 
that at protein concentrations below 40 mg/mL self-association of the tested protein samples was low. 
In turn, intensities of the signals marginally decreased with increasing concentrations of arginine 
glutamate. The observed decrease was proportional to increasing viscosity of the solution. 
During a second set of experiments, Kheddo and co-workers aimed to carry out stability 
investigations on monoclonal antibodies by combining proton NMR with size-exclusion 
chromatography. The corresponding investigations suggest, that with the aid of proton NMR, it was 
possible to quantify the amounts of both monomeric and low oligomeric protein concentrations that 
remain in the solution. As the result it was decided to employ the same method of analysis to monitor 
possible changes with monoclonal antibodies as well as the corresponding degradation with time in 
various formulations. The obtained results are summarised in figure 3.2 and 3.3. 
 
 
Figure 3.2: Representation of NMR long-term data, describing changes in monoclonal antibodies in 







Figure 3.3: Representation of NMR long-term data, describing changes in monoclonal antibodies in 
the analysed formulations, adapted from (Kheddo, et al., 2016, p. 1248). 
 
Figures 3.2 and 3.3 above show alterations in the analysed monoclonal antibody formulations in 
various arginine glutamate concentrations with time. In the figures 3.3, F represented changes in stability 
over time. As indicated by the observed trends addition of 200 mM of arginine glutamate substantially 
increased storage stability but only at pH 6, Figures 3.3E and F. As evident from the figures 3.3G and 
H at pH 7 introduction of arginine glutamate was similar to the addition of arginine hydrochloride. Long 
term stability was outlined on the figures 3.3G and F. It can be stated that arginine glutamate was not as 
effective as arginine hydrochloride in providing long-term protein stabilisation. 
In addition to the assessment above of formulation stability, proton NMR was employed to 
measure translational self-diffusion and rheometry. The results generated by Kheddo and co-workers 
indicated that protein aggregation could be reduced with the addition of arginine-glutamate to 
concentration dependent formulations (Kheddo, et al., 2016, p. 1249). The obtained stabilisation trends 
were supported by other publications (Golovanov, et al., 2004, p. 8933) (Hautbergue & Golovanov, 
2008, p. 336). 
 





The work described by Hamrang and co-workers on the application of orthogonal techniques for 
the analysis of stress-induced distributions and morphological changes in protein aggregates 
complement the work described by Kheddo and co-workers (Hamrang, et al., 2015, p. 2473) and 
discussed previously. In the work by Hamrang and co-workers it was suggested that physical methods 
of analysis could be used to determine correlations between thermal stress, particle concentration, 
aggregate morphology and distribution of particle sizes. In order to establish if there is any effect of 
thermal stress on concentration of sub-visible particles the research used two different concentrations 
of monoclonal antibodies, 1 and 10 mg/ml, in both treated and non-treated (temperature changes, 
changes in pH and buffer addition) monoclonal antibodies. Dynamic light scattering data showed lower 
number of detected protein particles in non-treated samples of monoclonal antibodies, compared with 
the corresponding samples that were stressed overnight at approximately 60oC.  
Hamrang et al then further investigated the correlation between distribution of particles and 
thermal stress. The corresponding particle size distributions were obtained using both MFI and RICS 
methods based on monoclonal antibodies. Subsequent statistical analysis of the data suggested that there 
were statistically significant differences between size distributions in the analysed particles, suggesting 
that thermal stress had an effect on the distribution of the thermally treated protein particles as expected. 
Finally, Hamrang and co-workers carried out a series of experiments aiming to characterise particle 
concentrations in terms of freeze-thaw treatment. Particle counts generated from the corresponding MFI 
analysis were compared with the generated freeze-thaw treatments that manifested substantial 
differences in sizes of the generated particles and their number. A considerable concentration dependent 
correlation was observed in the case of applying uncontrolled freeze-thaw stress. Thus, it was observed 
that in the case of 10 mg/mL protein samples a higher number of particles was observed when compared 
to the corresponding monoclonal antibody 1 mg/mL samples. The results obtained by Hamrang and co-
workers complement previously discussed publication by Kheddo and co-workers in terms of 
monoclonal antibody stability at various conditions (Hamrang, et al., 2015, p. 2477). 
By applying the analysis techniques outlined in the methodology section, it was possible to 
establish the culture viability effect that introduction of arginine glutamate has on both cell lines as well 
as primary fibroblast cells. This study indicated that it was necessary to investigate specific correlation 
between osmolality and viability of cell lines (Kheddo, et al., 2016, p. 91). In order to produce 
osmolalities ranging from 280 to 525 mOsm/kg, various excipients, such as arginine glutamate, sodium 
chloride, arginine chloride and sodium glutamate were employed. These salts were added to the 
corresponding cell containing solutions and results were obtained in the form of percentages of surviving 







Figure 3.4: The correlations between percentages of surviving cells and osmolality of the tested 
solutions (Kheddo, et al., 2016, p. 91) Trends were presented as correlations between percentage of 
viable cells versus cumulative osmolality (A, C) or solution concentration (B, D). The correlation 
between the tested salt concentrations and cumulative osmolality was represented on the figure E. In 
figure 3.4 above, the corresponding correlation between concentration of the introduced salts and the 
observed osmolality levels are outlined in plot E. In turn, culture viability was established with the aid 
of a flow cytometer and is presented in the format of the proportion of cells that survive. Correlations 
between the percentage of surviving cells and osmolality are outlined in figure 3.4A, while the effect 
of solution concentration on culture viability is represented in figure 3.4B. 
 
While assessing culture viability as represented in figure 3.4, the baseline level of viability was 
established as 90% of surviving cells. Looking at the data in figure 3.4, from the trends presented it was 





glutamate and results in a reduction in culture viability to approximately 50% and rising osmolarity to 
a level of 450 mOsm/kg. In turn, implementation of arginine hydrochloride to change osmolality had a 
much more negative effect on culture viability with a reduction to 45% at osmolality levels of 
approximately 380 mOsm/kg.  
Trends presented in figure 3.4B suggest that during the assessment on a mole of salt per mole 
basis it is possible to superimpose the cytotoxicity profiles of arginine glutamate and sodium glutamate, 
while addition of sodium chloride and arginine hydrochloride resulted in the highest impact on culture 
viability with reduction of viable cells below 50% at a concentration of 100 mM. Finally, the data 
presented in figure 3.4 suggested that arginine glutamate had the lowest impact on viability of culture. 
Nevertheless, a different pattern was observed in the case when human fibroblasts were cultured in the 
presence of arginine glutamate and the described above salts. For instance, according to the data 
presented in figure 3.4C and 3.4D, introduction of higher doses of reagents had a negative effect on 
culture viability (Kheddo, et al., 2016, p. 91). 
 
3.3 Investigation of dynamical allostery effects in mutated scFV antibody fragments and 
stabilising/destabilising effects 
In the study reported by Ramaprasad and co-workers, various computational methods were 
employed to investigate dynamical allostery observed in mutated scFv antibody fragments as well as 
the corresponding stabilising and destabilising effects that influence the integrity of the analysed protein 
(Ramaprasad et al., 2017, p. 2). Previous reports in the area have identified that, in many cases, mutated 
scFv antibodies shared similar activity (Miller, et al., 2010, p. 550). From a structural perspective the 
corresponding mutants contained a heavy and a light domain, connected through a flexible linker 
composed of 116-132 amino acid residues. As indicated and discussed in the previous sections of this 
thesis, dynamical allostery may be established through MSF changes, associated with external 
perturbations with subsequent comparison of response/perturbation profiles (Miller, et al., 2010, p. 550). 
 
3.4. Oxm self-assembles into fibrillar nanostructures 
Immediately after thioflavin was applied to Oxm, there was a characteristic fluruoscece 






Structural property of free and fibrillar Oxm, Adapted from (Ouberai et al., 2017, P. 3). 
 
Structural properties of free and fibrillar Oxm. a–d Free (black) and fibrillar (blue) Oxm at 1 mg 
mL−1 in 0.09% saline. Far-UV CD a, ATR-FT-IR, b and ThT emission spectra c, and DLS analysis 
(Error bars represent standard deviations obtained from eight measurements of the same sample) d 
However, there was no omission observed in the presence of a freshly prepared Oxm. In contrast, 
the fibrillar Oxm sample contained significantly larger species, with a mean diameter of 825 nm. The 
group tends to show that Oxm can as well be converted, under very mild conditions and with a high 
yield, into fibrillar nanostructures displaying amyloid-like features. In figure 2c abover, there was a 
clear shift in of the size of species present in the solution.  
 
3.5. Protein concentration effects on albumin solution viscosity 
Perturbations in proteins (particularly mutations of specific residues) resulting in stabilising and 
destabilising effects are also expected to change rheology of the corresponding protein solutions. Thus, 





substantially affected by concentration of the protein in solution. The results describing solution 
rheology experimentation are summarised in figure 3.6 below. 
 
Figure 3.6: Rheology data of human recombinant albumin solutions, adapted from (Goncalves, et al., 
2013, p. 10) 
 
In figure 3.6A above, rheology investigations on recombinant albumin samples were carried out 
at protein concentrations ranging from 0.1 to 100 mg/mL. In turn, in figure 3.6B protein concentrations 
ranging from 10 mg/mL to 500 mg/mL were used. In figure 3.6C, flow curves describing the rheology 
of albumin solutions with concentrations ranging from 10 mg/mL to 500 mg/mL are shown (Goncalves, 
et al., 2013, p. 10). 
Based on the data represented in figure 3.6, it can be seen that solutions of recombinant albumin 
manifest constant sheer viscosities at shear rates rising from 0.01 to 1000 s-1. In turn, a linear increase 
in the shear stress was observed with the application of higher shear rates as may be expected. 
Additionally, increases in viscosity were observed with increasing concentrations of the tested protein 
solution. Correlations between protein concentrations and viscosity of the corresponding solutions as 
well as correlations between protein concentrations and peak areas were therefore investigated and these 






Figure 3.7: Correlation plots between protein concentration, viscosity and peak area, adapted from 
(Goncalves, et al., 2013, p. 10). 
 
In figure 3.7 above it can be seen that viscosity of protein solutions increased with increase in 
the concentration of the tested protein as expected. Thus, chromatography experiments suggested that 
higher aggregation levels were detected at higher protein concentrations (Goncalves, et al., 2013, p. 10) 
in agreement with other studies. 
 
3.5 Aggregation kinetics of a pH-induced switch of human glucagon-like peptide 1 
In addition to aggregation due to increases in protein concentration, work by Zapadka and co-
workers indicated that aggregation kinetics were affected by changes in pH of the corresponding protein 
solutions (Zapadka, et al., 2016, p. 2). By application of the experimental procedures outlined in the 
methods section, it was possible to describe aggregation kinetics of GLP-1 and present the findings as 
correlations between peptide concentrations at various pH levels. Zapadka and co-workers were also 
able to describe size distributions of the analysed species in the prepared protein samples (Zapadka, et 






Figure 3.8: GLP-1 aggregation kinetics represented as a function between various pH levels and 
protein concentrations, adapted from (Zapadka, et al., 2016, p. 3) 
 
In figure 3.8 above, aggregation kinetics of GLP-1 at pH 7.5 are presented in figure 3.8A and 
3.8B, at pH 7.7 in figures 3.8C and 3.8D, and at pH 8.2 in figures 3.8E and 3.8F. Figures 3.8A, C and 
E represent fibrillation traces of GLP-1 that was followed by fluorescence of the obtained samples at 
various concentrations of GLP-1. In all concentrations triplet runs describing the behaviour of the 
analysed samples were obtained. Finally, in figures 3.8D, E and F the corresponding correlation between 
GLP-1 concentration and aggregation half-time (t1/2) is described. Standard deviations that corresponded 
to the established aggregation kinetics parameters were outlined in the form of errors bars (Zapadka, et 






Figure 3.9: Representation of size distributions of protein samples at various pH levels, adapted from 
(Zapadka, et al., 2016, p. 3) 
 
In figure 3.9 above, size distributions were assessed at various pH values, including 7.5 (figure 
3.9A and B), 8.0 (figure 3.9C and D) and 8.5 (figure 3.9E and F). The right-hand column represents the 
sedimentation results obtained by using AUC analysis of sedimentation velocity while the left-hand 






4.0 General Discussion 
Monoclonal antibody-based drugs have been established as novel and highly effective type of 
modern pharmaceutical product that have the potential to substantially increase the efficiency of the 
available treatment methods and develop novel methods of treatment for a variety of diseases. 
Publications, discussed in the work presented here, as well as the corresponding experimental findings 
outlined in these publications, indicate that various instrumental methods of analysis could be employed 
to characterise monoclonal antibody-based formulations, investigate interactions of individual proteins 
and draw conclusions regarding possible agglomeration as the result of changes in concentration, 
temperature and pH of the analysed solution (Kheddo, et al., 2016, p. 1246) (Kheddo, et al., 2016, p. 
88) (Zapadka, et al., 2016, p. 2) (ScienceDirect, 2018). 
Proton NMR spectroscopy was found to be highly effective in the characterisation of protein 
interactions in monoclonal antibody-based formulations containing various concentrations of arginine 
glutamate and arginine hydrochloride (Kheddo, et al., 2016, p. 1257) (Kheddo, et al., 2016, p. 88). In 
addition to the application to proton NMR for the characterisation of monoclonal antibody formulations, 
literature sources (Hamrang, et al., 2015, p. 2475) suggest that characterisation of the corresponding 
stress-induced protein aggregates along with determination of size distributions and description of 
morphological changes may be conducted with the aid of orthogonal analysis techniques, including 
combinations of thermal stress protocols, freeze-thaw protocols, confocal microscopy and application 
of dynamic light scattering (Hamrang, et al., 2015, p. 2475). Kheddo and co-workers showed that 
introduction of arginine glutamate (section 2.3) as well as arginine-based salts had a positive effect on 
the stabilisation of the corresponding monoclonal antibody-based formulations (Kheddo, et al., 2016, p. 
1257) (Kheddo, et al., 2016, p. 88). However, when considering the established effects of arginine 
glutamate as well as sodium chloride on viability of cells (i.e. addition during cell culture, not just during 
final formulation of the product) it was determined that with the introduction of higher concentrations 
of these additives, culture viability was reduced. In turn, analysis of the observed viability reduction 
indicated that the reduced culture viability was primarily associated with osmolality changes with no 
cell mortality due to inflammation. These findings, as well as the corresponding techniques employed 
during the assessment of culture viability, may subsequently be extrapolated to other analytical studies 
(Kheddo, et al., 2016, p. 88) (Kheddo, et al., 2016, p. 1257). 
The work by Kheddo and co-workers and that describe by Hamrang and co-workers were 
focused on the application of different methods of instrumental analysis in the assessment of culture 
viability as well as characterisation of physical processes placed upon monoclonal antibodies during 
their formulation and introduction into biological systems (Kheddo, et al., 2016, p. 88) (Kheddo, et al., 





that protein stabilising and destabilising effects were of paramount importance to the assessment of 
dynamical allostery processes taking place in mutated scFv antibody fragments (Ramaprasad et al., 
2017, p. 1). Thus, Hamrang and co-workers showed that even minor alterations in the analysed antibody 
fragments had a considerable effect on the resulting agglomeration of proteins in the respective 
formulations. Similarly, as outlined in the work by Kheddo and co-workers and of Hamrang and co-
workers, it was determined that physical methods of analysis were highly effective in monitoring and 
undertaking stability assessments as well as determination of conformational changes to provide an 
indication of the most significant factors affecting stabilisation of monoclonal antibody formulations 
(Kheddo, et al., 2014, p. 127) (Kheddo, et al., 2016, p. 88) (Kheddo, et al., 2014, p. 127) (Ramaprasad 
et al., 2017, p. 3) (Hamrang, et al., 2015, p. 2473). 
The remaining publications presented and analysed in this thesis were focused on the 
determination of the effects that changes in concentration of proteins had on viscosity of  albumin 
formulations and investigations of the effects that changes in pH had on protein agglomeration and 
stability. Both publications presented are fundamentally important as they explore and describe the 
behaviour of proteins under various physiological conditions and formulations relevant to the 
biopharmaceutical industry. The corresponding findings may subsequently be extrapolated to 
monoclonal antibody-based formulations with the possibility of developing novel, more stable and more 
potent drugs (Goncalves, et al., 2013, p. 1) (Zapadka, et al., 2016, p. 2). Considering the effect that 
protein concentration had on alteration in viscosity of the final protein solution, Goncalves and co-
workers indicated that the biophysical characteristics and correlations could be expanded to the 
description of the rheological behaviour as well as the content of protein species in both dilute, as well 
as highly concentrated, albumin solutions (Goncalves, et al., 2013, p. 2). This is particularly important 
as in most cases biotherapeutic proteins are formulated at high concentrations but many measurements 
on aggregation of such formulations are undertaken on diluted samples that can result in a changing of 
the aggregates present. Thus, approaches such as NMR and rheology that can study the protein solutions 
in the final formulation and concentration are likely to unravel and reveal insights into the behaviour of 
such proteins that is not revealed when analysing these in diluted samples. 
Analysis of the shear rheology results suggests that the observed patterns followed a Newtonian 
behaviour. The observed trends and correlations can be explained by the presence of polysorbate-80 in 
the protein solutions. Introduction of this surfactant is common in pharmaceutical practice and its 
addition results in negation of rheological properties as well as surfactant tension that is expected with 
the addition of water and formation of protein films on the interface between air and water (Goncalves, 





The results obtained in the study by Goncalves and co-workers clearly demonstrated that protein 
concentration had an effect on the viscosity which increased with protein concentration (Goncalves, et 
al., 2013, p. 2). In particular, this study established that the highest viscosity increase was detected in 
cases when protein concentration was increased from 250 to 500 mg/mL. At the concentration of 
approximately 500 mg/ml, the highest sample viscosity was observed. As mentioned in the previous 
sections, the indicated patterns could be employed in the design of monoclonal antibody-based 
formulations and design more stable and more concentrated biopharmaceutical formulations but that 
can ensure that viscosity does not become problematic or ‘too high’ (Goncalves, et al., 2013, p. 3). The 
findings are further supported by the corresponding data obtained using high pressure size exclusion 
chromatography. It was initially presumed that increases in viscosity were associated with protein 
agglomeration through protein-protein interactions. Whilst this may indeed be the case, the observed 
viscosity was affected by additional environmental factors including temperature of the solution, flow 
rate and nature of the mobile phase buffer (Goncalves, et al., 2013, p. 3). 
The work reported by Goncalves and co-workers is of importance to the development of modern 
biopharmaceutical products because principles applied to the analysis of albumin formulations can be 
expanded to monoclonal antibody-based formulations and other types of pharmaceutical products where 
protein agglomeration is observed (Goncalves, et al., 2013, p. 3). In summarising the experimental data 
that were obtained from this research, it should be indicated that at high protein concentrations, in 
addition to protein-protein interactions, additional formulation and storage/environmental specific 
factors should be taken into consideration during the assessment of correlations between viscosity and 
protein concentration. Consequently, during the development of monoclonal antibody-based drugs, 
factors such as possible interaction areas in the globular structure of proteins and their volume should 
be considered (Goncalves, et al., 2013, p. 3). 
Looking at specific cases of developing monoclonal antibody formulations, Kheddo and co-
workers indicated that undesired high viscosity in various mAb formulations may considerably promote 
reversible self-association of the corresponding proteins which may result in irreversible structural 
changes at high concentrations (Kheddo, et al., 2016, p. 1252). Irreversible agglomeration may 
considerably reduce the activity of the formulations and for this reason implementation of analytical 
monitoring and analysis techniques is essential in order to maintain the initial product activity and 
prevent agglomeration. Nuclear magnetic resonance spectroscopy was found to be a highly potent and 
versatile analytical technique that may be employed in various cases when speed and precision are 
required. Kheddo and co-workers showed that this technique was highly sensitive towards analysis of 
monoclonal antibodies and determination of possible formation of agglomerates (Kheddo, et al., 2016, 





to obtain data of adequate accuracy. These conditions include specific pH of the sample, temperature of 
the media and possible presence of additives. It was shown that proton NMR was highly effective during 
the analysis and characterisation of unlabelled and large monoclonal antibody proteins. The research 
indicated that the corresponding production of NMR data may be carried out automatically and 
conclusions on possible formation of agglomerates could be drawn based on maximisation of the signal 
intensity. It should also be noted that the application of traditional assays (e.g. testing of new drugs 
determined based on qualitative structure-activity relationships) may be highly beneficial at early stages 
of the analysis of monoclonal antibody-based formulations and the implementation of NMR techniques 
may be beneficial at later stages when detailed understanding of protein-protein and protein-solvent 
interactions are required (Kheddo, et al., 2016, p. 1252). 
In addition to the 1D NMR signals, Kheddo and co-workers suggested that NMR long-range 
data was also important in the assessment of formulation stabilities and optimisation of formulations. 
The NMR spectroscopy approach may be employed to determine various NMR measurements, 
including relaxation rates and translational diffusion data. The work in the publication by Kheddo and 
co-workers complements previously reported literature findings on correlations between viscosity of 
protein and concentration. The unique feature of NMR spectroscopy was to provide highly diverse 
information, covering in situ sample behaviour. Also, the discussed analytical technique can be 
employed to characterise conformational states of the analysed proteins, quantities of both monomeric 
and oligomeric protein species in the solution as well as complement corresponding chromatography 
data and light scattering. The data describe in the here highlights the importance of investigation into 
the possibility of using other instrumental methods of analysis in the characterisation of monoclonal 
antibodies (Kheddo, et al., 2014, p. 129) (Kheddo, et al., 2016, p. 89) (Kheddo, et al., 2014, p. 127) 







In analysing the data and papers presented here it is important to note that the formulation of 
antibodies for use in the clinic is the last step between production of the drug and administration into 
humans. Being able to stabilise an antibody and provide it in a suitable form for delivery is therefore an 
important part of the whole manufacturing of such drugs. A range of physical and chemical methods 
can be employed to study conformational changes in the corresponding monoclonal antibody-based 
formulations and how changes to formulations impact on various attributes indicative of antibody 
stability (e.g. aggregation, fragmentation, activity). The outlined work detailed here suggests that 
characterisation of monoclonal antibody-based formulations could effectively be enhanced with the aid 
of proton NMR spectroscopy. It can also be suggested that in addition to the discussed stable monoclonal 
antibodies, the corresponding NMR techniques may also be expanded to other less stable materials to 
aid in formulation development. 
In addition to proton NMR spectroscopy, the work described here has shown that various 
analytical techniques may also be used to complement analysis of monoclonal antibodies and determine 
aggregate size ranges in response to the application of various external factors. For example, by applying 
the RICS technique to the generation of particle size data it is possible to obtain information not biased 
to specific range of particle sizes, which highlights the importance of the corresponding technique in 
sizing of protein-based aggregates. From the data presented it can also be concluded that sizing 
characterisation of monoclonal antibody-based formulations is of paramount importance for adequate 
description of various novel and highly perspective pro-drugs. 
In addition to investigating the impact of excipients on the final formulation of antibodies, the 
work presented here investigated the ability of excipients to maintain the stability of a monoclonal 
antibody whilst in culture in the cell culture media and the impact on the culture viability and protein 
product stability. Assessing the behaviour of both adherent and non-adherent cell lines the findings of 
this work indicated that in all cases similar toxicity patterns were observed upon introduction of arginine 
glutamate. Thus, it can be concluded that changes in toxicity were primarily dictated by osmolarity 
changes. The data also suggests that non-inflammatory processes dictate cellular death upon 
introduction of sodium chloride. Comparing the activity of arginine glutamate with sodium chloride it 
was found that both compounds manifest similar cellular toxicity but at different concentrations. 
Introduction of both osmolarity-forming compounds is not expected to result in inflammations. Analysis 
of the stabilising and destabilising effects in both normal and mutated ScFv antibodies suggested that 
the corresponding responses were based on the nature of the perturbations taking place in the analysed 





stabilisation of individual fragments is expected to take place as the result of interaction with solute 
molecules.  
The studies on human recombinant albumin highlight the importance of protein-protein 
interactions during formulation of the corresponding pharmaceutical product. The results of studies that 
were carried out on recombinant human albumin and the corresponding correlations between protein 
concentration, viscosity and agglomeration can potentially be expanded to monoclonal antibodies 
during the development of mAb-based formulations. Finally, analysis of the kinetics of GLP-1 
aggregation was monitored at pH 7.5. It was observed that the lag time increased with increases in the 
peptide concentration. For this reason, it can be concluded that formation of unexpected and 
uncharacterised oligomeric species took place at the indicated pH level, which promoted further 
agglomeration of monomers. Development of the described agglomeration and aggregation pathway 
may lead to the transformation of the initial off-pathway oligomers into the corresponding on-pathway 
oligomers with subsequent development of fibrils. It is clear that due to intrinsic structural features of 
GLP-1, fibrils that are formed at pH=7.5 are unstable and short. Subsequent increase in the pH level 
results in the disruption of the formed bonds and development of aggregation pathways proceeding 
according to traditional nucleation mechanisms.  
Collectively, the discussed papers and work presented here reinforces the fact that the 
development of monoclonal antibody-based drugs is a highly challenging, but perspective field of the 
modern pharmaceutical industry. Thus, implementation of monoclonal antibodies in the treatment of 
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